Exactly fifty years after the ban on psychedelics a group of Zen meditators – who have never used any psychedelic substances before – are given psilocybin on the last day of a 5-day retreat. Half the group receives a placebo.

There are neurophysiological and phenomenological overlaps between psychedelic and meditative states, but there is little evidence on how exposure to psychedelics might be associated with meditation-related variables. We assessed lifetime classic psychedelic use, ego dissolution during one's most intense experience using a classic psychedelic, and exposure to meditation in a representative sample (n = 953) of American adults.

The resurgence of research into psychedelics has continued to thrive over the past year. Dozens of trials and hundreds of studies have been published in 2021.

Ketamine treatment was well tolerated and was also helpful.

Results revealed that lifetime MDMA/ecstasy and/or psilocybin use were associated with significantly lowered odds of a lifetime MDE ... and past year severe MDE.

These results indicate that 10 mg and 25 mg doses of psilocybin were generally well tolerated when given to up to six participants simultaneously ...

The published data suggest that ibogaine is an effective therapeutic intervention within the context of SUDs, reducing withdrawal symptoms and craving.

A significant number of Americans are already “self-medicating” with PM

Our randomised controlled phase IIb study of psilocybin therapy in treatment-resistant depression is the largest psilocybin therapy clinical trial ever conducted

Two recent studies raise the exciting possibility that it could be both safe and helpful to add psilocybin-assisted therapy to SSRI's.

We set an agenda for a psychedelic science of spirituality and religion, based on a synthesis of attachment theory with the Relaxed Beliefs Under pSychedelics (REBUS) model.

The majority of US addiction specialists, including psychiatrists, believe psychedelics are promising for the treatment of substance use disorders.

Understanding the mechanisms of action and evaluating their synergistic efficacy in scientific studies will be critical to advance the framework of psychedelic-assisted therapy for addiction.

We review data related to expectation and placebo effects, but argue that claims that microdosing effects are largely due to expectancy are premature and possibly wrong.

The present study provides a systematic and in-depth analysis of the nuanced content of the otherworldly encounter within the breakthrough DMT experience.

Focusing on the Research Domain Criteria (RDoC) as a template, we will describe the multimodal mechanisms underlying the transdiagnostic therapeutic effects of psychedelic therapy

Abusing psychoactive substances has been a popular sport in the business world since the mid-19th century.

Psychedelics are uniquely capable of reliably occasioning mystical experiences in ordinary humans without contemplative or religious backgrounds.

This model expands ACT by integrating practises and data from psychedelic-assisted therapy research.

NHS psychiatrists are positive about the potential for psychedelic-assisted therapy to advance psychiatric practise.